Advancing Small-Molecule Discovery with AI: Boltz Gains Momentum AI-native drug discovery company Boltz has announced a $28 million seed financing alongside a strategic collaboration with Pfizer, marking a significant step forward in the application of artificial intelligence to small-molecule drug discovery. The newly raised capital will support the expansion of Boltz’s platform, which is designed…
Breakthrough in Small-Molecule Discovery Targets “Undruggable” Cancers A research team at UCLA Health Jonsson Comprehensive Cancer Center has identified a novel small molecule that could unlock an entirely new class of cancer treatments—particularly for malignancies long considered difficult or impossible to treat. The newly discovered compound targets IGF2BP3, an RNA-binding protein that plays a key…
Small-Molecule Drug Discovery in 2025 Where the Market Stands—and How Far It Could Grow by 2030–2035 Small molecules—typically orally available, chemically synthesized drugs—remain the workhorse modality of modern therapeutics. In 2025, they continue to anchor pipelines across oncology, immunology, cardiovascular disease, and CNS, thanks to their ability to reach intracellular targets, scale reliably, and follow…
AI-Driven Molecular Representation Advances Scaffold Hopping A New Era for Small-Molecule Drug Discovery Small-molecule therapeutics remain foundational to modern medicine, supporting treatment across oncology, immunology, cardiovascular disease, and CNS disorders. Yet identifying new molecules with the right balance of potency, selectivity, and pharmacokinetic properties remains one of the most persistent challenges in drug discovery. One…